Skip to main content
Top
Published in: Clinical Rheumatology 4/2018

01-04-2018 | Original Article

Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes

Authors: Mara Felicetti, Diego Cazzador, Roberto Padoan, Alfonso Luca Pendolino, Chiara Faccioli, Ennio Nardello, Alvise Berti, Marina Silvestrini, Giuseppe Paolazzi, Giuliano Brunori, Elisabetta Zanoletti, Enzo Emanuelli, Alessandro Martini, Franco Schiavon

Published in: Clinical Rheumatology | Issue 4/2018

Login to get access

Abstract

Ear, nose and throat (ENT) manifestations in granulomatosis with polyangiitis (GPA) represent the most frequent symptoms at disease onset. The aim of the study was to analyse ENT involvement at diagnosis, as well as how it could influence relapse rate, mortality and disease severity. A retrospective non-controlled cohort study was performed including all consecutive diagnosed GPA from 1996 to 2016 in two rheumatology centres of Northern Italy, focusing particularly on ENT presenting signs and symptoms at baseline. Eighty-nine patients (48.3% females) with new onset GPA were evaluated. They were mostly Caucasian (97.7%), middle aged (mean 54.5 years) and more frequently anti-neutrophil cytoplasmic antibodies (ANCA) positive (78.6%) with PR3 specificity (81.4%). At diagnosis, ENT involvement was reported in 71.9% patients, second only to systemic symptoms. These patients were significantly younger at disease onset (0.013), with less frequent renal involvement (0.014) irrespectively to ANCA status, but with significantly higher Vasculitis Damage Index (VDI) (0.001). The most frequent ENT manifestation was sinonasal involvement (58.4%, 73% of which with nasal inflammation/chronic sinusitis and 48% with nasal crusting), while otologic involvement (mainly otitis media/otomastoiditis) was observed in 34.8%. ENT-GPA patients presented a higher survival rate at 5 years (98.1 vs 77.7%, 0.049), and ENT involvement resulted to be an independent predictor of better outcome (OR 0.37, 95% CI 0.2–0.8, 0.019). Our data confirms that ENT involvement is not only one of the key clinical features of GPA, but also could point out a milder GPA subset with lower renal involvement and lower mortality rate, irrespectively to ANCA status.
Literature
1.
go back to reference Falk RJ, Gross WL, Guillevin L, Hoffman GS, Jayne DRW, Jennette JC, Kallenberg CGM, Luqmani R, Mahr AD, Matteson EL, Merkel PA, Specks U, Watts RA, American College of Rheumatology, American Society of Nephrology, European League Against Rheumatism (2011) Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Arthritis Rheum 63(4):863–864. https://doi.org/10.1002/art.30286 CrossRefPubMed Falk RJ, Gross WL, Guillevin L, Hoffman GS, Jayne DRW, Jennette JC, Kallenberg CGM, Luqmani R, Mahr AD, Matteson EL, Merkel PA, Specks U, Watts RA, American College of Rheumatology, American Society of Nephrology, European League Against Rheumatism (2011) Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Arthritis Rheum 63(4):863–864. https://​doi.​org/​10.​1002/​art.​30286 CrossRefPubMed
3.
go back to reference Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA (1996) The epidemiology of Wegener’s granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 39(1):87–92. https://doi.org/10.1002/art.1780390112 CrossRefPubMed Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA (1996) The epidemiology of Wegener’s granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 39(1):87–92. https://​doi.​org/​10.​1002/​art.​1780390112 CrossRefPubMed
4.
5.
go back to reference Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CGM, Merkel PA, Raspe H, Salvarani C, Scott DGI, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R, for the European Vasculitis Study Group (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68(3):310–317. https://doi.org/10.1136/ard.2008.088096 CrossRefPubMed Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CGM, Merkel PA, Raspe H, Salvarani C, Scott DGI, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R, for the European Vasculitis Study Group (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68(3):310–317. https://​doi.​org/​10.​1136/​ard.​2008.​088096 CrossRefPubMed
9.
go back to reference Jennings CR, Jones NS, Dugar J, Powell RJ, Lowe J (1998) Wegener’s granulomatosis—a review of diagnosis and treatment in 53 subjects. Rhinology 36(4):188–191PubMed Jennings CR, Jones NS, Dugar J, Powell RJ, Lowe J (1998) Wegener’s granulomatosis—a review of diagnosis and treatment in 53 subjects. Rhinology 36(4):188–191PubMed
13.
14.
go back to reference Schirmer JH, Wright MN, Herrmann K et al (2016) Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener’s) is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German vasculitis referral center. Arthritis Rheumatol (Hoboken, N.J.) 68(12):2953–2963CrossRef Schirmer JH, Wright MN, Herrmann K et al (2016) Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener’s) is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German vasculitis referral center. Arthritis Rheumatol (Hoboken, N.J.) 68(12):2953–2963CrossRef
15.
go back to reference Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66(2):222–227. https://doi.org/10.1136/ard.2006.054593 CrossRefPubMed Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66(2):222–227. https://​doi.​org/​10.​1136/​ard.​2006.​054593 CrossRefPubMed
16.
19.
go back to reference Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup (2004) Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8(4):R204CrossRefPubMedPubMedCentral Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup (2004) Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8(4):R204CrossRefPubMedPubMedCentral
21.
go back to reference Rahmattulla C, de Lind van Wijngarden RA, Berden AE et al (2015) Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials. Rheumatology (Oxford) 54(5):899–907. https://doi.org/10.1093/rheumatology/keu357 CrossRef Rahmattulla C, de Lind van Wijngarden RA, Berden AE et al (2015) Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials. Rheumatology (Oxford) 54(5):899–907. https://​doi.​org/​10.​1093/​rheumatology/​keu357 CrossRef
23.
go back to reference Sproson EL, Jones NS, Al-Deiri M, Lanyon P (2007) Lessons learnt in the management of Wegener’s granulomatosis: long-term follow-up of 60 patients. Rhinology 45(1):63–67PubMed Sproson EL, Jones NS, Al-Deiri M, Lanyon P (2007) Lessons learnt in the management of Wegener’s granulomatosis: long-term follow-up of 60 patients. Rhinology 45(1):63–67PubMed
24.
27.
go back to reference Gottschlich S, Ambrosch P, Kramkowski D, Laudien M, Buchelt T, Gross WL, Hellmich B (2006) Head and neck manifestations of Wegener’s granulomatosis. Rhinology 44(4):227–233PubMed Gottschlich S, Ambrosch P, Kramkowski D, Laudien M, Buchelt T, Gross WL, Hellmich B (2006) Head and neck manifestations of Wegener’s granulomatosis. Rhinology 44(4):227–233PubMed
30.
go back to reference Pavone L, Grasselli C, Chierici E, Maggiore U, Garini G, Ronda N, Manganelli P, Pesci A, Rioda WT, Tumiati B, Pavesi G, Vaglio A, Buzio C, Secondary and Primar Vasculitides (Se.Pri.Va) Study Group (2006) Outcome and prognostic factors during the course of primary small-vessel vasculitides. J Rheumatol 33(7):1299–1306PubMed Pavone L, Grasselli C, Chierici E, Maggiore U, Garini G, Ronda N, Manganelli P, Pesci A, Rioda WT, Tumiati B, Pavesi G, Vaglio A, Buzio C, Secondary and Primar Vasculitides (Se.Pri.Va) Study Group (2006) Outcome and prognostic factors during the course of primary small-vessel vasculitides. J Rheumatol 33(7):1299–1306PubMed
33.
go back to reference Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, Nachman PH, Jennette JC, Falk RJ (2012) Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 64(10):3452–3462. https://doi.org/10.1002/art.34562 CrossRefPubMedPubMedCentral Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, Nachman PH, Jennette JC, Falk RJ (2012) Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 64(10):3452–3462. https://​doi.​org/​10.​1002/​art.​34562 CrossRefPubMedPubMedCentral
34.
go back to reference Pagnoux C, Carette S, Khalidi NA et al (2015) Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol 33(2 Suppl 89):S-77–S-83 Pagnoux C, Carette S, Khalidi NA et al (2015) Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol 33(2 Suppl 89):S-77–S-83
35.
go back to reference Córdova-Sánchez BM, Mejía-Vilet JM, Morales-Buenrostro LE, Loyola-Rodríguez G, Uribe-Uribe NO, Correa-Rotter R (2016) Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement. Clin Rheumatol 35(7):1805–1816. https://doi.org/10.1007/s10067-016-3195-z CrossRefPubMed Córdova-Sánchez BM, Mejía-Vilet JM, Morales-Buenrostro LE, Loyola-Rodríguez G, Uribe-Uribe NO, Correa-Rotter R (2016) Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement. Clin Rheumatol 35(7):1805–1816. https://​doi.​org/​10.​1007/​s10067-016-3195-z CrossRefPubMed
36.
go back to reference Mahr A, Katsahian S, Varet H, Guillevin L, Hagen EC, Höglund P, Merkel PA, Pagnoux C, Rasmussen N, Westman K, Jayne DRW, for the French Vasculitis Study Group (FVSG) and the European Vasculitis Society (EUVAS) (2013) Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis 72(6):1003–1010. https://doi.org/10.1136/annrheumdis-2012-201750 CrossRefPubMed Mahr A, Katsahian S, Varet H, Guillevin L, Hagen EC, Höglund P, Merkel PA, Pagnoux C, Rasmussen N, Westman K, Jayne DRW, for the French Vasculitis Study Group (FVSG) and the European Vasculitis Society (EUVAS) (2013) Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis 72(6):1003–1010. https://​doi.​org/​10.​1136/​annrheumdis-2012-201750 CrossRefPubMed
37.
go back to reference Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Hoglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K, for the European Vasculitis Study Group (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70(3):488–494. https://doi.org/10.1136/ard.2010.137778 CrossRefPubMed Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Hoglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K, for the European Vasculitis Study Group (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70(3):488–494. https://​doi.​org/​10.​1136/​ard.​2010.​137778 CrossRefPubMed
Metadata
Title
Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes
Authors
Mara Felicetti
Diego Cazzador
Roberto Padoan
Alfonso Luca Pendolino
Chiara Faccioli
Ennio Nardello
Alvise Berti
Marina Silvestrini
Giuseppe Paolazzi
Giuliano Brunori
Elisabetta Zanoletti
Enzo Emanuelli
Alessandro Martini
Franco Schiavon
Publication date
01-04-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 4/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4019-0

Other articles of this Issue 4/2018

Clinical Rheumatology 4/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.